Developing innovative cancer immunotherapies


Speaker: Assist. Prof. Adil Doganay Duru, NSU Cell Therapy Institute

Venue: A-2, Milkyway seminar room, SciLifeLab, Solna

Host: Adnane Achour, adnane.achour@ki.se

 

Related Research:

Engineering antigen-specific NK cell lines against the melanoma-associated antigen tyrosinase via TCR gene transfer. Parlar A, Sayitoglu EC, Ozkazanc D, Georgoudaki AM, Pamukcu C, Aras M, Josey BJ, Chrobok M, Branecki S, Zahedimaram P, Ikromzoda L, Alici E, Erman B, Duru AD*, Sutlu T*. Eur J Immunol. 2019 Aug;49(8):1278-1290. doi: 10.1002/eji.201948140. Epub 2019 May 17. PubMed PMID: 31054264. *Authors contributed equally
For the first time, a functional TCR complex and MHC-restricted antigen specificity was introduced to NK cells. US patent application #PCT/US2018/012403.

Boosting Natural Killer cells-mediated targeting of sarcoma through DNAM-1 and NKG2D. Sayitoglu EC*, Georgoudaki AM*, Chrobok M*, Josey BJ, Ozkazanc D, Kusser K, Hartman M, Chinn T, Krueger R, Alici E, HT Temple, Sutlu T, Duru AD. (Frontiers in Immunology in press) (* denotes equal contribution)